

9 November 2021

## Lupus Pharma

**Question 1: What guidelines or protocols do you refer to regarding the management of patients with:**

**a) Systemic lupus erythematosus (SLE)**

- The EULAR recommendations for the management of systemic lupus erythematosus (2019)
- The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults (2017)

**b) Lupus nephritis (LN)**

- 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis
- The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults (2017)

**Question 2: Please detail the number of patients that were admitted as an inpatient or day case in the last 12 months for the following primary diagnosis:**

Data supplied is from 1 September 2020 to 31 August 2021, the latest available dates with coding completed.

	<b>Diagnosis (ICD10 code)</b>
<b>Patient number and care setting</b>	<b>Systemic lupus erythematosus with organ or system involvement (M321)</b>
<b>Inpatient admission</b>	5
<b>Day case</b>	11

**Question 3: Do you refer patients within the ICD10 code M321 to another Trust?**

Response: No

**Question 4: Is there a specific clinic for LN patients at your Trust?**

9 November 2021

Response: No

**Question 5: Please complete the number of patients prescribed with the following products in the last 12 months within the ICD10 code Systemic lupus erythematosus with organ or system involvement (M321):**

The information requested is not collated centrally and an extensive trawl of patient notes would be required.

We estimate that compliance with this request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

	<b>Diagnosis (ICD10 code)</b>
<b>Product</b>	<b>Systemic lupus erythematosus with organ or system involvement (M321)</b>
<b>Azathioprine</b>	
<b>Belimumab</b>	
<b>Ciclosporin</b>	
<b>Cyclophosphamide</b>	
<b>Mycophenolate mofetil</b>	
<b>Oral tacrolimus</b>	

**Question 6: Has a shared care agreement/arrangement been established between your institution and primary care for the treatment of lupus nephritis? If you answered 'Yes', which of the following medicines can be prescribed within the shared care agreement?**

	<b>Azathioprine</b>	<b>Ciclosporin</b>	<b>Cyclophosphamide</b>	<b>Mycophenolate mofetil (MMF)</b>	<b>Oral tacrolimus</b>
<b>Yes/No</b>	Yes	Yes	Yes – for oral	Yes	Yes

**Question 7: Has a shared care agreement/arrangement been established between your institution and a tertiary centre for the treatment of lupus nephritis? If so, please specify what medicines can be prescribed in secondary care within these shared care agreements.**

Response: No

**Question 8: What is the name of your local integrated care system?**

Response: No formal pathway currently in place

9 November 2021

**Question 9: For the LN patient pathway, is care commissioned by:**

Response: No formal pathway currently in place

	<b>Activity</b>	<b>Block contract</b>	<b>Blended payment</b>
<b>Yes</b>			
<b>No</b>			